Research map: Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)

Back to the article

Papers in this map

  1. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma · Thomas B. Powles · 2021 · 1236 citations · Cited by this paper
  2. Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis · 2025 · Related
  3. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer · Thomas B. Powles · 2024 · 1079 citations · Cited by this paper
  4. Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer · 2026 · Related
  5. Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models · Pia M. Challita-Eid · 2016 · 738 citations · Cited by this paper
  6. MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies · 2025 · Related
  7. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma · Yohann Loriot · 2023 · 337 citations · Cited by this paper
  8. Targeting DNA Damage Repair Pathways Beyond PARP Inhibition · 2025 · Related
  9. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up · Thomas B. Powles · 2023 · 228 citations · Cited by this paper
  10. Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA · 2026 · Related
  11. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma · Thomas B. Powles · 2024 · 184 citations · Cited by this paper
  12. Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges · 2026 · Related
  13. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study · Enrique Grande · 2023 · 59 citations · Cited by this paper
  14. Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer · 2026 · Related
  15. Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients · Xiaojuan Zhou · 2023 · 38 citations · Cited by this paper
  16. Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma? · 2026 · Related
  17. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach · Shirly Grynberg · 2023 · 38 citations · Cited by this paper
  18. Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis · 2025 · Related
  19. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy. · Srikala S. Sridhar · 2023 · 33 citations · Cited by this paper
  20. A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer · 2025 · Related
  21. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience · Dimitra Rafailia Bakaloudi · 2023 · 30 citations · Cited by this paper
  22. Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US · Vinay Mathew Thomas · 2024 · 28 citations · Cited by this paper
  23. J‐AVENUE: A retrospective, real‐world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first‐line maintenance therapy in Japan · Eiji Kikuchi · 2024 · 26 citations · Cited by this paper
  24. Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study · Petros D. Grivas · 2024 · 19 citations · Cited by this paper
  25. The 50 years' war: The history and outcomes of the National Cancer Act of 1971 · Otis Webb Brawley · 2021 · 18 citations · Cited by this paper
  26. READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma · Lorenzo Antonuzzo · 2024 · 18 citations · Cited by this paper
  27. Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States · Helen Moon · 2024 · 16 citations · Cited by this paper
  28. Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program · Se Hoon Park · 2024 · 13 citations · Cited by this paper
  29. Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON ‐2 Retrospective Experience · Mimma Rizzo · 2025 · 9 citations · Cited by this paper
  30. Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain · Ahmet Hasaligil · 2025 · 2 citations · Cited by this paper
  31. Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study · Katrin Schlack · 2025 · 2 citations · Cited by this paper
  32. Untitled · Cited by this paper
  33. Untitled · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper
  36. Untitled · Cited by this paper
  37. Untitled · Cited by this paper
  38. Untitled · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)